AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32016387 — intervention group
Group type: EXPERIMENTAL
Intervention: FSD (irinotecan, 5-fluorouracil, leucovorin with standard quality CT)
Number of subjects: 667
Study 32016387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab-containing sets (FCHQ and FCSD)
Number of subjects: 667
Study 36123597 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation program (thematic quality circles, e‐learning, basic expenditure reimbursements, additional bonus payments, computerized decision support system)
Number of subjects: 312
Study 36123597 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based additional bonus payment
Number of subjects: 312
Study 36123597 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning participation
Number of subjects: 312
Study 36123597 — intervention group
Group type: EXPERIMENTAL
Intervention: Expenditure reimbursement
Number of subjects: 312
Study 36123597 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' views on implementation
Number of subjects: 312
Study 34087659 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen throughout surgery and for the first two postoperative hours
Number of subjects: 260
Study 34087659 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen throughout surgery and for the first two postoperative hours
Number of subjects: 260
Study 34087659 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen
Number of subjects: 260
Study 34087659 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 260
Study 32428523 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) solution
Number of subjects: 302
Study 32428523 — intervention group
Group type: COMPARATOR
Intervention: 5% sodium fluoride (NaF) varnish
Number of subjects: 302
Study 36352742 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented rapeseed meal (FRSM)
Number of subjects: 140
Study 36352742 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed meal (RSM)
Number of subjects: 140
Study 36352742 — intervention group
Group type: COMPARATOR
Intervention: Rapeseed meal (RSM) or Fermented rapeseed meal (FRSM) at 100%
Number of subjects: 140
Study 36352742 — intervention group
Group type: COMPARATOR
Intervention: All experimental treatments (including RSM and FRSM)
Number of subjects: 140
Study 36352742 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing levels of RSM or FRSM
Number of subjects: 140
Study 33383536 — intervention group
Group type: EXPERIMENTAL
Intervention: GJH group (Beighton score ≥ 4)
Number of subjects: 489
Study 35282567 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutta-percha
Number of subjects: 20
Study 35282567 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA) and gutta-percha
Number of subjects: 20
Study 35282567 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutta-percha and glass-fiber posts
Number of subjects: 20
Study 35282567 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA and glass-fiber posts
Number of subjects: 20
Study 35282567 — intervention group
Group type: COMPARATOR
Intervention: Control (prefilling scan)
Number of subjects: 20
Study 35282567 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide 80∗50 mm FOV
Number of subjects: 20
Study 33433820 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined classroom/parental intervention
Number of subjects: 5029
Study 33433820 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5029
Study 32865857 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsychosocial functional activity program (12-month intervention with a 6-week teaching program followed by home follow-up)
Number of subjects: 0
Study 32865857 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35324507 — intervention group
Group type: EXPERIMENTAL
Intervention: DTxP (digital therapeutics, virtual reality, psychological intervention for pain)
Number of subjects: 42
Study 35324507 — intervention group
Group type: EXPERIMENTAL
Intervention: DTxP
Number of subjects: 42
Study 35324507 — intervention group
Group type: COMPARATOR
Intervention: Sham placebo
Number of subjects: 42
Study 35324507 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 42
Study 33165251 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-focused literacy intervention (Reach Out and Read)
Number of subjects: 38
Study 33165251 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements (preintervention)
Number of subjects: 38
Study 34826022 — intervention group
Group type: EXPERIMENTAL
Intervention: 1927 nm thulium laser (FTL)
Number of subjects: 27
Study 34826022 — intervention group
Group type: COMPARATOR
Intervention: 2940 nm Er:YAG laser (FEL)
Number of subjects: 27
Study 33993685 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 patients
Number of subjects: 187
Study 33993685 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 patients with interstitial pneumonia
Number of subjects: 187
Study 33993685 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 patients without interstitial pneumonia
Number of subjects: 187
Study 33993685 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 patients with mild COVID-19
Number of subjects: 187
Study 33993685 — intervention group
Group type: COMPARATOR
Intervention: Blood donors
Number of subjects: 187
Study 33993685 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 patients with active EBV infection markers
Number of subjects: 187
Study 32363634 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 736
Study 32363634 — intervention group
Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 736
Study 34605016 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction Tube Uterine Tamponade (STUT)
Number of subjects: 24
Study 34605016 — intervention group
Group type: COMPARATOR
Intervention: Routine Uterine Balloon Tamponade (UBT)
Number of subjects: 24
Study 32435860 — intervention group
Group type: EXPERIMENTAL
Intervention: Module-based training for nurses
Number of subjects: 68
Study 32435860 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 68
Study 34482594 — intervention group
Group type: EXPERIMENTAL
Intervention: EBP mentor development programs
Number of subjects: 15
Study 33056960 — intervention group
Group type: EXPERIMENTAL
Intervention: Femto‐DSEK
Number of subjects: 37
Study 33056960 — intervention group
Group type: COMPARATOR
Intervention: DSAEK
Number of subjects: 37
Study 35157830 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg orally twice daily)
Number of subjects: 245
Study 35157830 — intervention group
Group type: COMPARATOR
Intervention: Control (enzalutamide 160 mg orally once daily or abiraterone 1000 mg orally once daily plus prednisone 5 mg orally twice daily)
Number of subjects: 245
Study 35157830 — intervention group
Group type: COMPARATOR
Intervention: Control (enzalutamide or abiraterone)
Number of subjects: 245
Study 34987314 — intervention group
Group type: EXPERIMENTAL
Intervention: MAVIG X-ray protective drape (MXPD)
Number of subjects: 60
Study 36360996 — intervention group
Group type: EXPERIMENTAL
Intervention: TaU + MIND (treatment as usual plus mindfulness-based therapy)
Number of subjects: 177
Study 36360996 — intervention group
Group type: COMPARATOR
Intervention: TaU (treatment as usual)
Number of subjects: 177
Study 33081717 — intervention group
Group type: EXPERIMENTAL
Intervention: HP‐diet and β‐cryptoxanthin
Number of subjects: 92
Study 33081717 — intervention group
Group type: COMPARATOR
Intervention: HP‐diet
Number of subjects: 92
Study 33081717 — intervention group
Group type: COMPARATOR
Intervention: β‐cryptoxanthin
Number of subjects: 92
Study 33081717 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 92
Study 35197097 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction model for pneumonia after AADS
Number of subjects: 492
Study 35197097 — intervention group
Group type: EXPERIMENTAL
Intervention: Training set multivariate analysis
Number of subjects: 492
Study 35197097 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration of the model
Number of subjects: 492
Study 35197097 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination of the model
Number of subjects: 492
Study 34337667 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength assessment
Number of subjects: 0
Study 34541872 — intervention group
Group type: EXPERIMENTAL
Intervention: RG‐TFV rectal gel daily
Number of subjects: 195
Study 34541872 — intervention group
Group type: EXPERIMENTAL
Intervention: RG‐TFV rectal gel before and after receptive anal intercourse (RAI)
Number of subjects: 195
Study 34541872 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral FTC/TDF
Number of subjects: 195
Study 34541872 — intervention group
Group type: COMPARATOR
Intervention: All three PrEP regimens (RG‐TFV daily, RG‐TFV before and after RAI, and daily oral FTC/TDF)
Number of subjects: 195
Study 32050782 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 300 mg
Number of subjects: 237
Study 32050782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 33412602 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention for critical care provision
Number of subjects: 1431
Study 33412602 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 1431
Study 35809658 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic-haptic junction oriented vertically
Number of subjects: 163
Study 35809658 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic-haptic junction oriented horizontally
Number of subjects: 163
Study 35809658 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic-haptic junction oriented superonasally
Number of subjects: 163
Study 35809658 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic-haptic junction oriented inferonasally
Number of subjects: 163
Study 35809658 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 163
Study 34284804 — intervention group
Group type: EXPERIMENTAL
Intervention: Elos 2.0 Programme
Number of subjects: 3800
Study 34284804 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3800
Study 34556559 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine chest pressure with direct current cardioversion from the first defibrillation shock.
Number of subjects: 0
Study 34556559 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving four sequential biphasic shocks of 150 J, 200 J, 360 J and 360 J with chest pressure on the last shock.
Number of subjects: 0
Study 36055860 — intervention group
Group type: EXPERIMENTAL
Intervention: MobileNet deep learning model
Number of subjects: 479
Study 33784761 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of parietal peritoneum and reapproximation of rectus muscle (group 3)
Number of subjects: 180
Study 33784761 — intervention group
Group type: COMPARATOR
Intervention: Closure of parietal peritoneum only (group 2)
Number of subjects: 180
Study 33784761 — intervention group
Group type: COMPARATOR
Intervention: Both parietal peritoneum and rectus abdominis muscle left open (group 1)
Number of subjects: 180
Study 33784761 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine requirements
Number of subjects: 180
Study 33784761 — intervention group
Group type: EXPERIMENTAL
Intervention: Return of bowel motility
Number of subjects: 180
Study 32332289 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical patients ages 0-<2
Number of subjects: 175878
Study 32332289 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical patients ages 2-<6
Number of subjects: 175878
Study 32332289 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical patients ages 6-<12
Number of subjects: 175878
Study 32332289 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical patients ages 12-18
Number of subjects: 175878
Study 32332289 — intervention group
Group type: EXPERIMENTAL
Intervention: All age groups of surgical patients
Number of subjects: 175878
Study 32332289 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical patients
Number of subjects: 175878
Study 33395734 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Group 2 (n=18) received a booklet, a tailored care plan, and four coaching sessions
Number of subjects: 25
Study 33395734 — intervention group
Group type: COMPARATOR
Intervention: Treatment Group 1 (n=7) received an educational booklet
Number of subjects: 25
Study 33285517 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) intervention facilitating accurate prognostic awareness (PA)
Number of subjects: 460
Study 33285517 — intervention group
Group type: COMPARATOR
Intervention: Control arm (symptom-management education)
Number of subjects: 460
Study 35050957 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitrous oxide/oxygen (N2O/O2) 50%-50% equimolar mixture (EMONO)
Number of subjects: 92
Study 35050957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 32964918 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 21 g (300 mg/kg) for 20 hours
Number of subjects: 135
Study 32964918 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose 5%)
Number of subjects: 135
Study 32745306 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy for 5 days
Number of subjects: 20
Study 32745306 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric oxygen therapy for 3 days
Number of subjects: 20
Study 32745306 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen responders
Number of subjects: 20
Study 35930329 — intervention group
Group type: EXPERIMENTAL
Intervention: Fact-focused conversation (prompted about objective event elements)
Number of subjects: 100
Study 35930329 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-focused conversation (prompted about subjective reactions to the event)
Number of subjects: 100
Study 35930329 — intervention group
Group type: COMPARATOR
Intervention: Emotion-focused conversation
Number of subjects: 100
Study 35930329 — intervention group
Group type: COMPARATOR
Intervention: Fact-focused conversation
Number of subjects: 100
Study 32298202 — intervention group
Group type: EXPERIMENTAL
Intervention: CART-19 (high dose 5 × 10^8)
Number of subjects: 42
Study 32298202 — intervention group
Group type: COMPARATOR
Intervention: CART-19 (low dose 5 × 10^7)
Number of subjects: 42
Study 35144958 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT intervention (mHealth application, symptom watch, tailored health intervention) for 8 weeks with weekly activities including symptom monitoring, goal setting, and progress monitoring.
Number of subjects: 60
Study 35144958 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study 33765633 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic strengthening (4 weeks, 3 days/week)
Number of subjects: 24
Study 33765633 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic strengthening
Number of subjects: 24
Study 33765633 — intervention group
Group type: COMPARATOR
Intervention: Control group (tailored strengthening exercises with exercise bands)
Number of subjects: 24
Study 33765633 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 33433041 — intervention group
Group type: EXPERIMENTAL
Intervention: NB-UVB phototherapy plus 480 mg oral Polypodium leucotomos (PL) twice daily
Number of subjects: 44
Study 33433041 — intervention group
Group type: COMPARATOR
Intervention: NB-UVB phototherapy plus placebo
Number of subjects: 44
Study 34128884 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) at 42°C for 120 seconds plus oral alpha lipoic acid (ALA) 600 mg three times per day for 3 weeks then 600 mg once daily for 2 weeks
Number of subjects: 120
Study 34128884 — intervention group
Group type: COMPARATOR
Intervention: Pulsed radiofrequency (PRF) at 42°C for 120 seconds
Number of subjects: 120
Study 32844300 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fidelity inguinal canal model
Number of subjects: 106
Study 32844300 — intervention group
Group type: COMPARATOR
Intervention: Control group (no model)
Number of subjects: 106
Study 36328157 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (once daily for 3 months)
Number of subjects: 167
Study 36328157 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) anticoagulation (low molecular weight heparins or vitamin K antagonists)
Number of subjects: 167
Study 36328157 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (extension arm for 1 year)
Number of subjects: 167
Study 32682552 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP5 (5 cm H2O)
Number of subjects: 47
Study 32682552 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP8 (8 cm H2O)
Number of subjects: 47
Study 32682552 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP12 (12 cm H2O)
Number of subjects: 47
Study 34800474 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed HPV self-sampling kits
Number of subjects: 16590
Study 34800474 — intervention group
Group type: EXPERIMENTAL
Intervention: Completed cervical cancer screening (Pap)
Number of subjects: 16590
Study 33009645 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI+PWI using cryoballoon
Number of subjects: 366
Study 33009645 — intervention group
Group type: COMPARATOR
Intervention: PVI using cryoballoon
Number of subjects: 366
Study 34763370 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal music listening
Number of subjects: 38
Study 34763370 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental music listening
Number of subjects: 38
Study 34763370 — intervention group
Group type: COMPARATOR
Intervention: Audio books
Number of subjects: 38
Study 33615173 — intervention group
Group type: EXPERIMENTAL
Intervention: CIGB-325 (2.5 mg/kg/day during 5 consecutive days) plus standard-of-care
Number of subjects: 20
Study 33615173 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care alone
Number of subjects: 20
Study 34062308 — intervention group
Group type: EXPERIMENTAL
Intervention: IUI with letrozole
Number of subjects: 100
Study 34062308 — intervention group
Group type: COMPARATOR
Intervention: Natural cycle IUI
Number of subjects: 100
Study 34082177 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/kg natural oregano essential oil (NOEO)
Number of subjects: 384
Study 34082177 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/kg synthetic oregano essential oil (SOEO)
Number of subjects: 384
Study 34082177 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg colistin sulfate and 20 mg/kg virginiamycin (antibiotics)
Number of subjects: 384
Study 34082177 — intervention group
Group type: COMPARATOR
Intervention: Control diet (antibiotic-free)
Number of subjects: 384
Study 35505379 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive pictorial health education program
Number of subjects: 120
Study 35505379 — intervention group
Group type: COMPARATOR
Intervention: Routine community lecture health education
Number of subjects: 120
Study 32799723 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 160
Study 32799723 — intervention group
Group type: COMPARATOR
Intervention: Coffee consumption (provided three times a day)
Number of subjects: 160
Study 32799723 — intervention group
Group type: COMPARATOR
Intervention: Chewing sugar-free gum (for 15 min with an interval of 4 h from the second postoperative hour)
Number of subjects: 160
Study 32799723 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 160
Study 35872223 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated segmentation using a deep convolutional neural network (CNN) model
Number of subjects: 144
Study 35872223 — intervention group
Group type: COMPARATOR
Intervention: Manual segmentation
Number of subjects: 144
Study 32081599 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (5 mg/d)
Number of subjects: 40
Study 32081599 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg/d)
Number of subjects: 40
Study 35209851 — intervention group
Group type: EXPERIMENTAL
Intervention: New IMT/PEP device
Number of subjects: 80
Study 35209851 — intervention group
Group type: COMPARATOR
Intervention: Threshold IMT device
Number of subjects: 80
Study 33217836 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Xiaoyao Powder (MXP)
Number of subjects: 280
Study 33217836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study 35564356 — intervention group
Group type: EXPERIMENTAL
Intervention: NANO restoration with metal matrix (NANO-METAL)
Number of subjects: 40
Study 35564356 — intervention group
Group type: COMPARATOR
Intervention: NANO restoration with transparent matrix (NANO-TRANS)
Number of subjects: 40
Study 35564356 — intervention group
Group type: EXPERIMENTAL
Intervention: BFC restoration with metal matrix (BFC-METAL)
Number of subjects: 40
Study 35564356 — intervention group
Group type: COMPARATOR
Intervention: BFC restoration with transparent matrix (BFC-TRANS)
Number of subjects: 40
Study 35564356 — intervention group
Group type: EXPERIMENTAL
Intervention: NANO restoration
Number of subjects: 40
Study 34003726 — intervention group
Group type: EXPERIMENTAL
Intervention: A Program of SUPPORT
Number of subjects: 76
Study 34003726 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 76
Study 32282773 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonaggressive hydration (Hartmann's solution at 1.5 mL kg h for the first 24 hours and 30 mL kg during the next 24 hours)
Number of subjects: 88
Study 32282773 — intervention group
Group type: COMPARATOR
Intervention: Aggressive hydration (bolus of Hartmann's solution 20 mL kg, followed by an infusion of 3 mL kg h for the first 24 hours and then 30 mL kg for the next 24 hours)
Number of subjects: 88
Study 36273180 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally Focused Therapy (EFT) for couples, 19-21 sessions
Number of subjects: 140
Study 36273180 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group receiving psycho-educational program based on EFT after the study
Number of subjects: 140
Study 33575950 — intervention group
Group type: EXPERIMENTAL
Intervention: IR‐ESO (esomeprazole 20 mg and sodium bicarbonate 1100 mg)
Number of subjects: 40
Study 33575950 — intervention group
Group type: COMPARATOR
Intervention: ESO (esomeprazole delayed release tablet 20 mg)
Number of subjects: 40
Study 33575950 — intervention group
Group type: EXPERIMENTAL
Intervention: IR‐ESO and ESO
Number of subjects: 40